Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucas Resende Salgado

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of Gastrointestinal Oncology|December 2, 2014
Outcomes of rectal cancer with liver oligometastasesLucas Resende Salgado, Howard Hsu, Kevin Du
Brachytherapy|August 1, 2018
Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapyLucas Resende Salgado, Ryan Rhome, William Oh, et al.
Cureus|December 8, 2021
Comparison of Pathologic Complete Response Rates and Oncologic Outcomes in Patients With Surgically Resectable Esophageal Cancer Treated With Neoadjuvant Chemoradiation to 50.4 Gy vs 41.4 GyAnthony D Nehlsen, Eric J Lehrer, Lucas Resende-Salgado, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
Healthcare Disparities and Outcomes of Cancer Patients in a Community Setting from a COVID-19 EpicenterBrianna M Jones, Eric J Lehrer, Anurag Saraf, et al.
International Journal of Molecular Sciences|September 13, 2025
Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical StrategiesNicola J Nasser, Kunal K Sindhu, Loor Nasser, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
The Impact of Medicaid Expansion on Patients with Cancer in the United States: A ReviewAlexandra Hotca, Julie R Bloom, Juliana Runnels, et al.
Biology|December 22, 2023
Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell TherapyCatherine Yu, Kristin Hsieh, Daniel R Cherry, et al.
Frontiers in Oncology|January 7, 2016
Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal CancerDanielle S Bitterman, Lucas Resende Salgado, Harvey G Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2019
Utilization Patterns of Single Fraction Radiation Therapy for Multiple MyelomaLucas Resende Salgado, Sanders Chang, Meng Ru, et al.
Current Oncology (Toronto, Ont.)|April 27, 2026
Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future DirectionsLucas Resende Salgado, Osama Zaytoun, Ahmed Rabie, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Gastrointestinal Oncology|December 2, 2014
Outcomes of rectal cancer with liver oligometastasesLucas Resende Salgado, Howard Hsu, Kevin Du
Brachytherapy|August 1, 2018
Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapyLucas Resende Salgado, Ryan Rhome, William Oh, et al.
Cureus|December 8, 2021
Comparison of Pathologic Complete Response Rates and Oncologic Outcomes in Patients With Surgically Resectable Esophageal Cancer Treated With Neoadjuvant Chemoradiation to 50.4 Gy vs 41.4 GyAnthony D Nehlsen, Eric J Lehrer, Lucas Resende-Salgado, et al.
Current Oncology (Toronto, Ont.)|February 24, 2022
Healthcare Disparities and Outcomes of Cancer Patients in a Community Setting from a COVID-19 EpicenterBrianna M Jones, Eric J Lehrer, Anurag Saraf, et al.
International Journal of Molecular Sciences|September 13, 2025
Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical StrategiesNicola J Nasser, Kunal K Sindhu, Loor Nasser, et al.
Current Oncology (Toronto, Ont.)|July 28, 2023
The Impact of Medicaid Expansion on Patients with Cancer in the United States: A ReviewAlexandra Hotca, Julie R Bloom, Juliana Runnels, et al.
Biology|December 22, 2023
Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell TherapyCatherine Yu, Kristin Hsieh, Daniel R Cherry, et al.
Frontiers in Oncology|January 7, 2016
Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal CancerDanielle S Bitterman, Lucas Resende Salgado, Harvey G Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 25, 2019
Utilization Patterns of Single Fraction Radiation Therapy for Multiple MyelomaLucas Resende Salgado, Sanders Chang, Meng Ru, et al.
Current Oncology (Toronto, Ont.)|April 27, 2026
Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future DirectionsLucas Resende Salgado, Osama Zaytoun, Ahmed Rabie, et al.
Pageof 3